FY2029 EPS Estimates for TSE:MSL Raised by HC Wainwright

Merus Labs International Inc. (TSE:MSL) (NASDAQ:MSLI) – Equities research analysts at HC Wainwright boosted their FY2029 earnings per share estimates for Merus Labs International in a research report issued to clients and investors on Thursday, July 9th. HC Wainwright analyst A. He now expects that the specialty pharmaceutical company will post earnings of ($1.22) per share for the year, up from their prior forecast of ($1.59). HC Wainwright also issued estimates for Merus Labs International’s FY2030 earnings at $1.32 EPS.

MSL has been the subject of several other research reports. Guggenheim upgraded shares of Merus Labs International to a “strong-buy” rating in a research report on Tuesday, April 28th. Canaccord Genuity Group upgraded shares of Merus Labs International to a “moderate buy” rating in a research report on Thursday, May 21st. Finally, Leerink Partners upgraded shares of Merus Labs International to a “strong-buy” rating in a research report on Monday, April 6th. Three investment analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Strong Buy”.

Merus Labs International Price Performance

Merus Labs International has a 52-week low of C$0.95 and a 52-week high of C$1.76.

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.